Clinical challenges of SARS‑CoV‑2 variants (Review)
- Authors:
- Cristian Cojocaru
- Elena Cojocaru
- Adina Magdalena Turcanu
- Dragos Cosmin Zaharia
-
Affiliations: Medical III Department, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Morpho‑Functional Sciences II Department, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department 4 Cardio‑thoracic Pathology, Faculty of Medicine, University of Medicine and Pharmacy ‘Carol Davila’, 050471 Bucharest, Romania - Published online on: April 28, 2022 https://doi.org/10.3892/etm.2022.11343
- Article Number: 416
-
Copyright: © Cojocaru et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Chan JF, To KK, Tse H, Jin DY and Yuen KY: Interspecies transmission and emergence of novel viruses: Lessons from bats and birds. Trends Microbiol. 21:544–555. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al: A novel coronavirus from patients with Pneumonia in China. N Engl J Med. 382:727–733. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y and Gao G: Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 24:490–502. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579:270–273. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, et al: A new coronavirus associated with human respiratory disease in China. Nature. 579:265–269. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Kistler K, Huddleston J and Bedford T: Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2. Cell Host Microbe. 30:545–555.e4. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Khan A, Khan T, Ali S, Aftab S, Wang Y, Qiankun W, Khan M, Suleman M, Ali S, Heng W, et al: SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines. Biomed Pharmacother. 143(112176)2021.PubMed/NCBI View Article : Google Scholar | |
|
World Health Organization (WHO): Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed January 19, 2022. | |
|
Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, Washburne AD, et al: Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 372(eabg3055)2021.PubMed/NCBI View Article : Google Scholar | |
|
Centers for Disease Control and Prevention (CDC): Science Brief: Emerging SARS-CoV-2 Variants. CDC, Atlanta, GA, 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html. Updated January 2021. | |
|
Letko M, Marzi A and Munster V: Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 5:562–569. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Hoffmann M, Kleine-Weber H and Pöhlmann S: A Multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 78:779–784.e5. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Yang W and Shaman J: Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern. Nat Commun. 12(5573)2021.PubMed/NCBI View Article : Google Scholar | |
|
Monel B, Planas D, Grzelak L, Smith N, Robillard N, Staropoli I, Goncalves P, Porrot F, Guivel-Benhassine F, Guinet ND, et al: Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: An observational retrospective study. EBioMedicine. 73(103637)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, Mayhew M, Megram O, Ashford F, White T, et al: S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by TaqPath Polymerase Chain Reaction. J Infect Dis. 223:1666–1670. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Calistri P, Amato L, Puglia I, Cito F, Di Giuseppe A, Danzetta ML, Morelli D, Di Domenico M, Caporale M, Scialabba S, et al: Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int J Infect Dis. 105:753–755. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Walker AS, Vihta KD, Gethings O, Pritchard E, Jones J, House T, Bell I, Bell JI, Newton JN, Farrar J, et al: Tracking the emergence of SARSCoV-2 alpha variant in the United Kingdom. N Engl J Med. 385:2582–2585. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Shenai MB, Rahme R and Noorchashm H: Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: A systematic review and pooled analysise. Cureus. 13(e19102)2021.PubMed/NCBI View Article : Google Scholar | |
|
Vassallo M, Manni S, Klotz C, Fabre R, Pini P, Blanchouin E, Sindt A, Lotte L, Dubertrand JM, Liguori S, et al: Patients admitted for variant alpha COVID-19 have poorer outcomes than those infected with the old strain. J Clin Med. 10(3550)2021.PubMed/NCBI View Article : Google Scholar | |
|
Turnbull CD, Porter BML, Evans SB, Smith O, Lardner R, Hallifax R, Bettinson HV, Talbot NP, Bafadhel M, Rahman NM, et al: Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant. BMJ open Respir Res. 8(e001044)2021.PubMed/NCBI View Article : Google Scholar | |
|
Elliott J, Whitaker M, Bodinier B, Eales O, Riley S, Ward H, Cooke G, Darzi A, Chadeau-Hyam M and Elliott P: Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people. PLoS Med. 18(e1003777)2021.PubMed/NCBI View Article : Google Scholar | |
|
Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, et al: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 9(e61312)2020.PubMed/NCBI View Article : Google Scholar | |
|
Resende P, Bezerra J, Teixeira Vasconcelos RH, Arantes I, Appolinario L, Mendonça AC, Paixao AC, Duarte Rodrigues AC, Silva T, Sampaio Rocha A, et al: Severe Acute Respiratory Syndrome Coronavirus 2 P.2 Lineage Associated with Reinfection Case, Brazil, June-October 2020. Emerg Infect Dis. 27:1789–1794. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, et al: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 592:616–622. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Moss DL and Rappaport J: SARS-CoV-2 beta variant substitutions alter spike glycoprotein receptor binding domain structure and stability. J Biol Chem. 297(101371)2021.PubMed/NCBI View Article : Google Scholar | |
|
Jassat W, Mudara C, Ozougwu L, Tempia S, Blumberg L, Davies MA, Pillay Y, Carter T, Morewane R, Wolmarans M, et al: Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: A cohort study. Lancet Glob Heal. 9:e1216–e1225. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Luna-Muschi A, Borges IC, de Faria E, Barboza AS, Maia FL, Leme MD, Guedes AR, Mendes-Correa MC, Kallas EG, Segurado AC, et al: Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: A prospective cohort study of vaccinated and unvaccinated healthcare workers. J Infect. 84:248–288. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Allen H, Vusirikala A, Flannagan J, Twohig KA, Zaidi A, Chudasama D, Lamagni T, Groves N, Turner C, Rawlinson C, et al: Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): National casecontrol study. Lancet Reg Health Eur. 12(100252)2022.PubMed/NCBI View Article : Google Scholar | |
|
Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, Rakshit P, Singh S, Abraham P, Panda S and Team N: SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms. 9(1542)2021.PubMed/NCBI View Article : Google Scholar | |
|
Challen R, Dyson L, Overton CE, Guzman-Rincon LM, Hill EM, Stage HB, Brooks-Pollock E, Pellis L, Scarabel F, Pascall DJ, et al: Early epidemiological signatures of novel SARS-CoV-2 variants: Establishment of B.1.617.2 in England. medRxiv: doi: https://doi.org/10.1101/2021.06.05.21258365. | |
|
Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, Shi J, Deng X, Jiang M, Zhong S, et al: Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 40(101129)2021.PubMed/NCBI View Article : Google Scholar | |
|
Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPHS, Lim YD, Lee PH, Lee TH, Chia PY, et al: Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) variants of concern: A retrospective cohort study comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clin Infect Dis: Aug 23, 2021 (Epub ahead of print). | |
|
Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, Seaman SR, Harris RJ, Hope R, Lopez-Bernal J, et al: Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: A cohort study. Lancet Infect Dis. 22:35–42. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Loconsole D, Centrone F, Morcavallo C, Campanella S, Accogli M, Sallustio A, Peccarisi D, Stufano A, Lovreglio P and Chironna M: Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy. Vaccines (Basel). 9(1354)2021.PubMed/NCBI View Article : Google Scholar | |
|
Ryu BH, Hong SI, Lim SJ, Cho Y, Hwang C, Kang H, Kim SH, Wi YM, Hong KW, Bae IG and Cho OH: Clinical Features of Adult COVID-19 Patients without Risk Factors before and after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant Outbreak in Korea: Experience from Gyeongsangnam-do. J Korean Med Sci. 36(e341)2021.PubMed/NCBI View Article : Google Scholar | |
|
Butt AA, Dargham SR, Chemaitelly H, Al Khal A, Tang P, Hasan MR, Coyle PV, Thomas AG, Borham AM, Concepcion EG, et al: Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. JAMA Intern Med. 182:197–205. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte JM, Mak TM, Cui L, Kalimuddin S, Chia WN, Tan CW, et al: Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: A multicentre cohort study. Clin Microbiol Infect. 28:612.e1–612.e7. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Kim S, Nguyen TT, Taitt AS, Jhun H, Park HY, Kim SH, Kim YG, Song EY, Lee Y, Yum H, et al: SARSCoV-2 omicron mutation is faster than the chase: Multiple mutations on spike/ACE2 interaction residues. Immune Netw. 21(e38)2021.PubMed/NCBI View Article : Google Scholar | |
|
Meo SA, Meo AS, Al-Jassir FF and Klonoff DC: Omicron SARS-CoV-2 new variant: Global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 25:8012–8018. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Sofonea MT, Roquebert B, Foulongne V, Verdurme L, Trombert-Paolantoni S, Roussel M, Haim-Boukobza S and Alizonet S: From Delta to Omicron: Analysing the SARS-CoV-2 epidemic in France using variant-specific screening tests (September 1 to December 18, 2021). medRxiv: doi: https://doi.org/10.1101/2021.12.31.21268583. | |
|
Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, Ramlall R, Spoor S, de Villiers T, Van der Walt Z, et al: Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. Int J Infect Dis. 116:38–42. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, Kläser K, Canas LS, Molteni E, Modat M, et al: Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study. Lancet Public Health. 6:e335–e345. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang S, Zou X, Li Z, Fu J, Fan H, Yu H, Deng F, Huang H, Peng J, Zhao K, et al: Analysis of clinical characteristics and virus strains variation of patients infected with SARS-CoV-2 in Jiangsu Province-A retrospective study. Front Public Health. 9(791600)2021.PubMed/NCBI View Article : Google Scholar | |
|
Neagu M, Constantin C and Surcel M: Testing antigens, antibodies, and immune cells in COVID-19 as a public health topic-experience and outlines. Int J Environ Res Public Health. 18(13173)2021.PubMed/NCBI View Article : Google Scholar | |
|
Lownik JC, Farrar JS, Way GW, McKay A, Roychoudhury P, Greninger AL and Martin RK: Fast SARS-CoV-2 variant detection using snapback primer high-resolution melting. Diagnostics (Basel). 11(1788)2021.PubMed/NCBI View Article : Google Scholar | |
|
de Puig H, Lee RA, Najjar D, Tan X, Soekensen LR, Angenent-Mari NM, Donghia NM, Weckman NE, Ory A, Ng CF, et al: Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants. Sci Adv. 7(eabh2944)2021.PubMed/NCBI View Article : Google Scholar | |
|
Lunca C, Cojocaru C, Gurzu IL, Petrariu FD and Cojocaru E: Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples. medRxiv: doi: https://doi.org/10.1101/2021.07.12.21260263. | |
|
Buchta C, Camp JV, Jovanovic J, Radler U, Benka B, Puchhammer-Stöckl E, Müller MM, Griesmacher A, Aberle SW and Görzer I: Inadequate design of mutation detection panels prevents interpretation of variants of concern: Results of an external quality assessment for SARS-CoV-2 variant detection. Clin Chem Lab Med. 60:291–298. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Ruan Q, Yang K, Wang W, Jiang L and Song J: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46:846–848. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ghebrehiwet B and Peerschke EI: Complement and coagulation: Key triggers of COVID-19-induced multiorgan pathology. J Clin Invest. 130:5674–5676. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Jacobs W, Lammens M, Kerckhofs A, Voets E, Van San E, Van Coillie S, Peleman C, Mergeay M, Sirimsi S, Matheeussen V, et al: Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature. ESC Hear Fail. 7:3772–3781. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Timpani CA and Rybalka E: Calming the (Cytokine) Storm: Dimethyl fumarate as a therapeutic candidate for COVID-19. Pharmaceuticals (Basel). 14(15)2020.PubMed/NCBI View Article : Google Scholar | |
|
Wood H: New insights into the neurological effects of COVID-19. Nat Rev Neurol. 16(403)2020.PubMed/NCBI View Article : Google Scholar | |
|
Cojocaru E, Cojocaru C, Antoniu SA, Stafie CS, Rajnoveanu A and Rajnoveanu RM: Inhaled interferons beta and SARS-COV2 infection: A preliminary therapeutic perspective. Expert Rev Respir Med. 16:257–261. 2022. | |
|
US Food and Drug (FDA): FDA Approves First COVID-19 Vaccine. FDA, Silver Spring, MD, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine. Accessed August 23, 2021. | |
|
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et al: Remdesivir for the treatment of Covid-19-Final Report. N Engl J Med. 383:1813–1826. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Lavinio A, Ercole A, Battaglini D, Magnoni S, Badenes R, Taccone FS, Helbok R, Thomas W, Pelosi P and Robba C: collaborators. Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: Observational report from 28 European intensive care units. Crit Care. 25(155)2021.PubMed/NCBI View Article : Google Scholar | |
|
Guy T, Créac'hcadec A, Ricordel C, Salé A, Arnouat B, Bizec JL, Langelot M, Lineau C, Marquette D, Martin F, et al: High-flow nasal oxygen: A safe, efficient treatment for COVID-19 patients not in an ICU. Eur Respir J. 56(2001154)2020.PubMed/NCBI View Article : Google Scholar | |
|
Horwitz LI, Jones SA, Cerfolio RJ, Francois F, Greco J, Rudy B and Petrilli CM: Trends in COVID-19 Risk-Adjusted Mortality Rates. J Hosp Med. 16:90–92. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Our World in Data: COVID-19 Data Explorer. https://ourworldindata.org/explorers/coronavirus-data-explorer. Accessed March 12, 2022. | |
|
Mercatelli D and Giorgi FM: Geographic and genomic distribution of SARS-CoV-2 mutations. Front Microbiol. 11(1800)2020.PubMed/NCBI View Article : Google Scholar | |
|
Shen Z, Xiao Y, Kang L, Ma W, Shi L, Zhang L, Zhou Z, Yang J, Zhong J, Yang D, et al: Genomic diversity of severe acute respiratory syndrome-coronavirus 2 in patients with coronavirus disease 2019. Clin Infect Dis. 71:713–720. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, Datir R, Collier DA, Albecka A, Singh S, et al: SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 599:114–119. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Long MJC and Aye Y: Science's Response to CoVID-19. ChemMedChem. 16:2288–2314. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Muik A, Wallisch AK, Sänger B, Swanson KA, Mühl J, Chen W, Cai H, Maurus D, Sarkar R, Türeci O, et al: Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 371:1152–1153. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Abdool Karim SS and de Oliveira T: New SARS-CoV-2 variants-clinical, public health, and vaccine implications. N Engl J Med. 384:1866–1868. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Pfizer: Pfizer and BioNTech Provide Update on Omicron Variant. Pfizer, New York, NY 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant. Accessed December 08, 2021. | |
|
Cojocaru C, Cojocaru E, Radu S and Gurzu B: Perception and attitude of the general population on the risk of infection with SARS-CoV-2. J Biosci Med. 9:1–10. 2021. | |
|
Congressional Research Service: Global Economic Effects of COVID-19, 2021. https://crsreports.congress.gov/. Updated November 10, 2021. |
